Literature DB >> 25201624

Reliability of the adult myopathy assessment tool in individuals with myositis.

Michael O Harris-Love1, Galen Joe, Todd E Davenport, Deloris Koziol, Kristen Abbett Rose, Joseph A Shrader, Olavo M Vasconcelos, Beverly McElroy, Marinos C Dalakas.   

Abstract

OBJECTIVE: The Adult Myopathy Assessment Tool (AMAT) is a 13-item performance-based battery developed to assess functional status and muscle endurance. The purpose of this study was to determine the intrarater and interrater reliability of the AMAT in adults with myositis.
METHODS: Nineteen raters (13 physical therapists and 6 physicians) scored videotaped recordings of patients with myositis performing the AMAT for a total of 114 tests and 1,482 item observations per session. Raters rescored the AMAT test and item observations during a followup session (mean ± SD 19 ± 6 days between scoring sessions). All raters completed a single, self-directed, electronic training module prior to the initial scoring session.
RESULTS: Intrarater and interrater reliability correlation coefficients were ≥0.94 for the AMAT functional subscale, endurance subscale, and total score (all P < 0.02 for Ho , ρ ≤0.75). All AMAT items had satisfactory intrarater agreement (kappa statistics with Fleiss-Cohen weights, with values κw = 0.57-1.00). Interrater agreement was acceptable for each AMAT item (κ = 0.56-0.89) except the sit up (κ = 0.16). The standard error of measurement and 95% confidence interval range for the AMAT total scores did not exceed 2 points across all observations (AMAT total score range 0-45).
CONCLUSION: The AMAT is a reliable, domain-specific assessment of functional status and muscle endurance for adult subjects with myositis. Results of this study suggest that physicians and physical therapists may reliably score the AMAT following a single training session. The AMAT functional subscale, endurance subscale, and total score exhibit interrater and intrarater reliability suitable for clinical and research use.
Copyright © 2015 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2015        PMID: 25201624      PMCID: PMC4450351          DOI: 10.1002/acr.22473

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  34 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials.

Authors:  Matthias J Müller; Armin Szegedi
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

3.  Functional testing.

Authors:  R T Moxley
Journal:  Muscle Nerve       Date:  1990       Impact factor: 3.217

Review 4.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 5.  Diagnosis and management of dermatomyositis.

Authors:  L B Adams-Gandhi; A S Boyd; L E King
Journal:  Compr Ther       Date:  1996-03

6.  Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis.

Authors:  Todd E Davenport; Joseph A Shrader; Beverly McElroy; Goran Rakocevic; Marinos Dalakas; Michael O Harris-Love
Journal:  Disabil Rehabil       Date:  2014-03-29       Impact factor: 3.033

7.  Statistical methodology for the concurrent assessment of interrater and intrarater reliability: using goniometric measurements as an example.

Authors:  M Eliasziw; S L Young; M G Woodbury; K Fryday-Field
Journal:  Phys Ther       Date:  1994-08

8.  Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

Authors:  Lindsay E Fernández-Rhodes; Angela D Kokkinis; Michelle J White; Charlotte A Watts; Sungyoung Auh; Neal O Jeffries; Joseph A Shrader; Tanya J Lehky; Li Li; Jennifer E Ryder; Ellen W Levy; Beth I Solomon; Michael O Harris-Love; Alison La Pean; Alice B Schindler; Cheunju Chen; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2011-01-06       Impact factor: 44.182

9.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  D J Lovell; C B Lindsley; R M Rennebohm; S H Ballinger; S L Bowyer; E H Giannini; J E Hicks; J E Levinson; R Mier; L M Pachman; M H Passo; M D Perez; A M Reed; K N Schikler; M Smith; L S Zemel; L G Rider
Journal:  Arthritis Rheum       Date:  1999-10

Review 10.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

View more
  4 in total

1.  Patient reported outcomes in GNE myopathy: incorporating a valid assessment of physical function in a rare disease.

Authors:  Christina Slota; Margaret Bevans; Li Yang; Joseph Shrader; Galen Joe; Nuria Carrillo
Journal:  Disabil Rehabil       Date:  2017-02-07       Impact factor: 3.033

2.  Functional Index-3: A Valid and Reliable Functional Outcome Assessment Measure in Patients With Dermatomyositis and Polymyositis.

Authors:  Floranne C Ernste; Christopher Chong; Cynthia S Crowson; Tanaz A Kermani; Orla Ni Mhuircheartaigh; Helene Alexanderson
Journal:  J Rheumatol       Date:  2020-04-15       Impact factor: 4.666

Review 3.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018

4.  Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods - a qualitative study.

Authors:  Alexander Oldroyd; William Dixon; Hector Chinoy; Kelly Howells
Journal:  BMC Rheumatol       Date:  2020-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.